{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:56:56Z","timestamp":1786985816938,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cca.2024.119963","type":"journal-article","created":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T17:44:10Z","timestamp":1725817450000},"page":"119963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Comparative assessment of trough and peak levels and AUC24 for amikacin in nontuberculous mycobacterial infection"],"prefix":"10.1016","volume":"565","author":[{"given":"Jiyeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Hoon","family":"Rim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehyeok","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanmil","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Baeck","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2024.119963_b0005","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40262-021-01000-6","article-title":"Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections","volume":"60","author":"Alffenaar","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cca.2024.119963_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114187","article-title":"Comprehensive lipid profiles investigation reveals host metabolic and immune alterations during anti-tuberculosis treatment: Implications for therapeutic monitoring","volume":"158","author":"Anh","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.cca.2024.119963_b0015","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cca.2024.119963_b0020","first-page":"11","article-title":"Diagnosis and Management of Pulmonary NTM with a Focus on Mycobacterium avium Complex and Mycobacterium abscessus: Challenges and Prospects","author":"Hendrix","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.cca.2024.119963_b0025","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00011-18","article-title":"Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease","volume":"62","author":"Jhun","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cca.2024.119963_b0030","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1080\/14656566.2021.1953472","article-title":"The role of amikacin in the treatment of nontuberculous mycobacterial disease","volume":"22","author":"Raaijmakers","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cca.2024.119963_b0035","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1093\/cid\/ciy613","article-title":"Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment","volume":"67","author":"Sturkenboom","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cca.2024.119963_b0040","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12931-022-02299-w","article-title":"Meeting the challenges of NTM-PD from the perspective of the organism and the disease process: innovations in drug development and delivery","volume":"23","author":"van der Laan","year":"2022","journal-title":"Respir Res"},{"key":"10.1016\/j.cca.2024.119963_b0045","doi-asserted-by":"crossref","first-page":"e1408","DOI":"10.1093\/cid\/ciac394","article-title":"Evaluation of Mycobacterium Avium Complex Pulmonary Disease Treatment Completion and Adherence to ATS\/IDSA Guidelines","volume":"76","author":"Ku","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cca.2024.119963_b0050","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.1128\/AAC.01050-15","article-title":"Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients","volume":"59","author":"Modongo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cca.2024.119963_b0055","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"Aminoglycosides","year":"2012"},{"key":"10.1016\/j.cca.2024.119963_b0060","first-page":"573","volume":"27","author":"Wargo","year":"2014","journal-title":"Aminoglycoside-Induced Nephrotoxicity. J Pharm Pract"},{"key":"10.1016\/j.cca.2024.119963_b0065","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.phrs.2018.07.005","article-title":"Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives","volume":"134","author":"de Velde","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cca.2024.119963_b0070","first-page":"9","article-title":"Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease","author":"Jin","year":"2020","journal-title":"Antibiotics (basel)"},{"key":"10.1016\/j.cca.2024.119963_b0075","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00228-023-03516-1","article-title":"Failure to predict amikacin elimination in critically ill patients with cancer based on the estimated glomerular filtration rate: applying PBPK approach in a therapeutic drug monitoring study","volume":"79","author":"Telles","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cca.2024.119963_b0080","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/ppul.24468","article-title":"Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis","volume":"54","author":"Caceres Guido","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.cca.2024.119963_b0085","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12931-023-02612-1","article-title":"Treatable traits and challenges in the clinical management of non-tuberculous mycobacteria lung disease in people with cystic fibrosis","volume":"24","author":"Gramegna","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.cca.2024.119963_b0090","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00877-18","article-title":"Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis","volume":"62","author":"Illamola","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cca.2024.119963_b0095","unstructured":"Medicine TASPAaM. AMINOGLYCOSIDE DOSING IN ADULT PATIENTS. Available from: https:\/\/www.med.umich.edu\/asp\/. 2023."},{"key":"10.1016\/j.cca.2024.119963_b0100","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/bcp.14542","article-title":"Evaluation of amikacin use and comparison of the models implemented in two Bayesian forecasting software packages to guide dosing","volume":"87","author":"Ryan","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cca.2024.119963_b0105","unstructured":"Sanford Guide. 2022. Available from: https:\/\/www.sanfordguide.com\/."},{"key":"10.1016\/j.cca.2024.119963_b0110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bjbas.2017.01.006","article-title":"Efficacy and toxicity of once versus twice daily regimens of amikacin in febrile neutropenic pediatric cancer patients","volume":"6","author":"Abd-Elfattah","year":"2017","journal-title":"Beni-Suef University Journal of Basic and Applied Sciences"},{"key":"10.1016\/j.cca.2024.119963_b0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsps.2010.11.001","article-title":"Once versus individualized multiple daily dosing of aminoglycosides in critically ill patients","volume":"19","author":"Abdel-Bari","year":"2011","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.cca.2024.119963_b0120","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/phar.2722","article-title":"Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta-analysis","volume":"42","author":"Abdelmessih","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cca.2024.119963_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113777","article-title":"Critical assessment of the revised guidelines for vancomycin therapeutic drug monitoring","volume":"155","author":"Aljutayli","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.cca.2024.119963_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104278","article-title":"Optimisation of vancomycin exposure in neonates based on the best level of evidence","volume":"154","author":"Dao","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cca.2024.119963_b0135","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cca.2024.119963_b0140","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2125.1995.tb05719.x","article-title":"A suggested approach to once-daily aminoglycoside dosing","volume":"39","author":"Begg","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cca.2024.119963_b0145","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00993-19","article-title":"Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic\/Pharmacodynamic Target Attainments in Individual Patients","volume":"63","author":"Boidin","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cca.2024.119963_b0150","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41579-020-0331-1","article-title":"Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus","volume":"18","author":"Johansen","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cca.2024.119963_b0155","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jgar.2019.05.027","article-title":"Evaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing Klebsiella pneumoniae ST405 strains","volume":"19","author":"Carcas","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cca.2024.119963_b0160","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jgar.2017.09.019","article-title":"Impact of amikacin pharmacokinetic\/pharmacodynamic index on treatment response in critically ill patients","volume":"12","author":"Ruiz","year":"2018","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124022162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124022162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:32Z","timestamp":1741046432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898124022162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":32,"alternative-id":["S0009898124022162"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2024.119963","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative assessment of trough and peak levels and AUC24 for amikacin in nontuberculous mycobacterial infection","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2024.119963","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"119963"}}